Davis Select U.S. Equity ETF (DUSA)
- Previous Close
38.81 - Open
38.75 - Bid 38.85 x 900
- Ask 38.91 x 900
- Day's Range
38.74 - 38.99 - 52 Week Range
28.14 - 40.59 - Volume
17,714 - Avg. Volume
28,216 - Net Assets 483.51M
- NAV 38.77
- PE Ratio (TTM) 15.29
- Yield 0.93%
- YTD Daily Total Return 10.07%
- Beta (5Y Monthly) 0.94
- Expense Ratio (net) 0.61%
Under normal market conditions, the fund will invest at least 80% of its net assets plus any borrowings for investment purposes in equity securities issued by U.S. companies. The fund's portfolio generally contains between 15 and 35 companies. It may invest a portion of its assets in financial services companies. The fund may also invest in mid- and small-capitalization companies, which the manager considers to be those companies with less than $10 billion in market capitalization. It may invest up to 20% of net assets in non-U.S. companies. The fund is non-diversified.
Davis ETFs
Fund Family
Large Blend
Fund Category
483.51M
Net Assets
2017-01-11
Inception Date
Performance Overview: DUSA
Trailing returns as of 4/18/2024. Category is Large Blend.
People Also Watch
Holdings: DUSA
Top 10 Holdings (68.07% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: DUSA
Daily – Vickers Top Buyers & Sellers for 11/17/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
ANIK: Lowering target price to $18.00
ANIKA THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $18.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Medium.
RatingNeutralPrice TargetANIK: What does Argus have to say about ANIK?
ANIKA THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice TargetANIK: Lowering target price to $20.00
ANIKA THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingNeutralPrice Target